Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vaccines Shakeup Continues In China: NT Pharma Backs Away From GSK

This article was originally published in The Pink Sheet Daily

Executive Summary

NT Pharma is positioning its decision as an effort to concentrate resources on becoming an end-to-end service provider, but the impact of the new 2010 Chinese Pharmacopoeia on vaccines manufactured by multinational companies may also have been a consideration.

You may also be interested in...

WuXi Celebrates First $100 Million Quarter; Sinovac Reports 50% Revenue Increase; SciClone Not Worried About Zydaxin Cuts: China Earnings Round Up (Part 1)

China's major players rack up double-digit growth in the second quarter, with WuXi PharmaTech celebrating its first $100 million quarter and Sinovac seeing a 50% increase in revenues. On the heels of the NovaMed acquisition, SciClone Pharmaceuticals Inc. is preparing to enter more markets in China and anticipates price cuts for its flagship product Zadaxin. In a recurring feature, PharmAsia News combs through earnings calls to bring readers the highlights in the critical emerging markets.

With Limits Created By China's New Pharmacopoeia, What's Next For Vaccine Manufacturers?

SHANGHAI - China is expected to be the world's largest vaccine market by 2020, and every vaccine maker is trying to increase their presence to gain market share. However, the new Chinese Pharmacopoeia might put these efforts to an end and almost all vaccines from multinational companies may have to withdraw from China if they fail to comply with new standards

GSK Buys Out Neptunus Stake in Chinese Vaccines JV; Are New Pharmacopoeia Standards At Play?

In an effort to increase its footprint in the Chinese vaccine market, GlaxoSmithKline PLC will acquire the remaining 51% equity stake in its joint venture with China's Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. for $39 million in cash, the companies announced June 14





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts